ArticleBMC rheumatology2024

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study.

Laura C Coates et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.